What does the mechanism of tirzepatide predict that SURMOUNT-OSA did not test?

The case in front of me: tirzepatide · SURMOUNT-OSA.

I would like the mechanism, because I want to be able to reason about the cases nobody has written about.

I have tried to reason it out from first principles and got to two contradictory conclusions.

So what is the mechanism, and how well established is it?

Answering this needs the distinction between the native hormone and the pharmacological agents, whose half-lives differ by three orders of magnitude and whose effects therefore differ in kind.

Glucose-dependence arises because the insulinotropic signal amplifies glucose-stimulated secretion rather than initiating secretion. With no glucose signal to amplify, there is little to amplify.

More usefully, gastric emptying delay attenuates with continued exposure for long-acting agents through receptor desensitisation, which is why the early nausea usually settles while the appetite effect persists.

A receptor being expressed in a tissue does not establish that activating it there matters at therapeutic exposures.

The half-life problem and the albumin-binding solution are the whole story of the class chemically.

edited 21 Aug 2026 by Dr_Elias_Weiss — reworded for clarity after a comment

The glucose-dependence is the key property. Below about four millimoles per litre the insulinotropic effect largely disappears, which is why monotherapy hypoglycaemia is uncommon.

Native GLP-1 has a circulating half-life of one to two minutes because dipeptidyl peptidase-4 cleaves the two N-terminal residues. Substituting the position-8 alanine, as the long-acting analogues do, blocks that cleavage and is the single most consequential modification in the class.

Glucagon suppression is also glucose-dependent and is lost during hypoglycaemia, which preserves the counter-regulatory response — a genuinely elegant piece of physiology and the reason the class is safe in this respect.

The incretin effect itself was established by comparing the insulin response to oral and intravenous glucose loads matched for plasma glucose; the difference is what the gut hormones contribute.

Mechanism is a good guide to what to expect and a poor guide to how much.

This is answerable mechanistically, and the mechanism actually predicts the side-effect profile, which is unusual and worth exploiting when reasoning about it.

Receptor density and downstream coupling differ between tissues, so the dose-response curves for glycaemia, weight and nausea are not the same curve. That is the pharmacological basis for titration.

On the detail: central effects reach the arcuate nucleus and the area postrema, regions with an incomplete blood-brain barrier. That anatomy is why a large peptide can act centrally at all, and it also explains the nausea, since the area postrema is the chemoreceptor trigger zone.

Area postrema involvement in nausea from this class is supported by lesion studies in animals and by the anatomy of the circumventricular organs.

Nothing here is medical advice; this is pharmacology.

Tissue distribution first, then signalling. Nearly every question in this tag resolves at the first step.

The honest answer is that appetite suppression is centrally mediated and gastric emptying is peripheral, and the two contribute different amounts in different people.

Albumin binding does the rest of the work. A fatty-acid chain attached through a linker binds circulating albumin reversibly, which both shields the peptide from renal clearance and creates a depot; that is how a two-minute hormone becomes a once-weekly drug.

Glucose-dependence is the property to remember; it explains the safety profile on its own.

The short version: glucose-dependent insulinotropic action, glucagon suppression, delayed gastric emptying and central appetite effects, from one receptor in four places.

Biased agonism — differential recruitment of beta-arrestin versus G-protein signalling — is an active research area and is one hypothesis for why agents with similar receptor affinity have different tolerability.

The position-8 substitution conferring DPP-4 resistance appears in essentially every long-acting agent in the class, which is about as strong a piece of convergent evidence as medicinal chemistry offers.

The caveat is that mechanism predicts direction and rarely predicts magnitude in an individual, and people reason from mechanism to dose far too confidently.

Nausea and appetite share an anatomy, which is why they are hard to separate by dose.